RESEARCH

Particles and corrected particles of LDL and non-HDL are stronger predictors of coronary lesion in postmenopausal women

Chuang Li1, Jingxun Chen2, Siyue Wei3, Mei Zhang1*, Yushun Chu4, Fanpeng Meng1, Jianyu Wang1, Jie Tang1, Jian Luo1, Yu Yang1, Xiulong Niu1 and Wei Cai1

Abstract

Background: The optimum lipid indexes, predicting the coronary lesion in postmenopausal women are not clear. 

Objective: To evaluate the optimum lipid predictor for coronary lesion in routine and advanced lipid tests. 

Method: 300 postmenopausal women were enrolled and assigned into coronary heart disease (CHD) Group (242), and non-CHD Group (58). Routine and advanced lipid indexes were measured with standard laboratory test and nuclear magnetic resonance (NMR) spectroscopy. The correlation and predictivities for CHD of routine and advanced lipid indexes were performed with Logistic regression, Spearman correlation analysis and receiver operating characteristic (ROC).

Results: Age (hazard ratio (HR) 2.58, 95% confidence interval (CI) 1.08–5.86, P = 0.03), apolipoprotein B (ApoB) (HR 1.35, 95% CI 1.15–1.59, P < 0.001), corrected particles of low-density lipoprotein (LDL-p-corr) (HR 1.05, 95% CI 1.03–1.06, P < 0.001) and corrected particles of non-high-density lipoprotein (non-HDL-p-corr) (HR 1.02, 95% CI 1.01–1.03, P < 0.001) were the risk factors of CHD. LDL cholesterol (LDL-C), LDL-p, LDL-p-corr, HDL cholesterol (HDL-C), non-HDL cholesterol (non-HDL-C), non-HDL-p and non-HDL-p-corr were in linear correlation with Gensini score. Advanced lipid indexes LDL-p (area under curve (AUC) = 0.750, P = 0.02), LDL-p-corr (AUC = 0.759, P = 0.02), non-HDL-p (AUC = 0.693, P = 0.03) and non-HDL-p-corr (AUC = 0.699, P = 0.03) were more predictive for CHD than the routine ones (LDL-C and non-HDL-C).

Conclusion: In postmenopausal women, age, ApoB, LDL-p-corr and non-HDL-p-corr were risk factors of CHD. Compared with traditional lipid items, LDL-p, LDL-p-corr, non-HDL-p and non-HDL-p-corr may be better lipid indexes for CHD in postmenopausal women.

Keywords: Coronary heart disease, Lipid test, Nuclear magnetic resonance spectroscopy, Postmenopausal females, Low-density lipoprotein cholesterol

Background

Cardiovascular disease (CVD) is the leading cause of death in women [1]. Dyslipidemia, especially high-level low-density lipoprotein cholesterol (LDL-C) plays an important role in the atherosclerotic cardiovascular disease (ASCVD) [2, 3]. Postmenopausal women are a special group of females, featured with increased LDL-C level and CVD risk [4, 5]. Hormonal changes,
estradiol (E2) mainly, are the partly cause of increased CVD risk for postmenopausal women. E2 is produced primarily in the ovaries with the substrate of LDL-C, and would decline up to 10 pg/mL in postmenopausal from 100 to 250 pg/mL in the fertile life [6]. Thus, postmenopausal women are at higher risk of developing ASCVD with increased LDL-C. As women live longer than men and average life span of women increasing, it was reported that one-third of women will live in postmenopausal state and the rate will be much higher by 2025 in developed countries [7]. As the recently published paper showed a growing prevalence of coronary heart disease (CHD) in women, and women have higher short- to medium-term mortality after myocardial infarction (MI) compared with men [8]. More attention should be paid to the prevention of ASCVD in women, especially in postmenopausal women.

The 2019 ESC/EAS Guidelines for the management of dyslipidemias [9] recommended total cholesterol (TC), LDL-C, high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG) as the routine lipid panel for all people and non-HDL-C for patients with high TG level, very low level of LDL-C, diabetes mellitus (DM) or obesity (I, C). But the routine lipid panel, lack of lipoprotein a (Lp(a)) and particles of lipoprotein, is not efficiency in ASCVD prevention, especially for postmenopausal women. It had been reported that Lp(a), which couldn't distinguish from LDL-C in routine lipid panel, was an independent risk factor for the presence and severity of new-onset coronary atherosclerotic disease (CAD) in postmenopausal women [10]. A series studies on the characteristics of HDL subgroups in postmenopausal women revealed that smaller HDL size and lower total and medium HDL particles (HDL-p) were associated with incident CVD, whereas lower large HDL-p was associated with extent of coronary calcification [11–13]. The particles of LDL (LDL-p) also appear to be a very strong predictor for CAD in women. In the Cardiovascular Health Study [14], LDL-p and smaller LDL-p size were associated with the incidence of CAD, especially in elderly women. Mackey et al.[13] also reported that LDL-p, small, dense LDL, and large very-low-density lipoprotein (VLDL) were positively associated with coronary artery calcification in healthy postmenopausal women. The last four studies were all based on nuclear magnetic resonance (NMR) spectroscopy, which is an advanced lipid measurement, can provide up to 112 lipid subclasses, 15 metabolites and 9 amino acids in one test. We performed this study in a group of postmenopausal women to find the optimum lipid indexes for predicting coronary atherosclerotic burden with the comparison of routine and advanced lipid items.

Method

Study populations

Postmenopausal inpatients, matching the inclusion and exclusion criteria, were enrolled in this study. Inclusion criteria: 1. Female, age > 46 years, natural menopause over 1 year; 2. Conducted CAG between June 2019 and June 2020; 3. All necessary data for this study were available; 4. Clear awareness, able to sign informed consent and willing to take blood measurements. Exclusion criteria: 1. Previous percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG); 2. Ovariectomy on either side; 3. Under taking lipid lowering medication; 4. Under taking estrogen replacement medication; 5. Cirrhosis or decompensated liver function (Child–Pugh Score > 6); 6. Abnormal renal function (estimated glomerular filtration rate < 60 mL/min/1.73 m²); 7. Unstable hemodynamics or left ventricular ejection fraction (LVEF) less than 30%; 8. Rheumatoid or systemic diseases such as sepsis; 9. Severe progressive diseases such as tumors. This study is approved by the ethics committee and conducted with signed consent of all participants in accordance with the Helsinki Declaration.

Study design

This was a single-center cross-sectional clinical study. Patients with any coronary stenosis ≥ 50% were assigned into CHD Group, with all coronary stenosis < 50% were assigned into non-CHD Group, according to CAG [15] (Fig. 1). The Gensini scores were calculated based on CAG. The clinical characters were collected from medical record system and blood samples were collected for routine lipid test, NMR spectroscopy and Lp(a) once included in this study. Clinical characters and lipid index were compared between the two groups.

CAG and Gensini score

The CAGs were performed for patients who had typical or untypical unstable angina pectoris along with myocardial ischemic changes in electrocardiogram, for example, single or multiple leads/territories ST-segment depression/elevation ≥1 mm, increased hyperacute T wave amplitude with prominent symmetrical T waves, pathologic Q waves, intraventricular bundle branch blocks, atrioventricular conduction delays, loss of precordial R wave amplitude, etc. Coronary plaque burden was evaluated by Gensini Score [16], which could qualify the severity of the coronary lesions by 3 main parameters: severity score, region multiplying factor and collateral adjustment factor.
Routine and advanced lipid parameters measurement and calculation

Fasting venous blood samples were collected the day before CAG, and stored at −70 °C after centrifugation. TC, TG, HDL-C, apolipoprotein A1 (ApoA1) and apolipoprotein B (ApoB) were tested in clinical laboratories with standard measurements. LDL-C was calculated with Friedewald formula. The particles of Lp(a) (Lp(a)-p) were measured in nmol/L by particle-enhanced turbidimetric immunoassay with Tina-quant Lipoprotein (a) Gen.2 (Latex) (LPA2) Roche® on Cobas system. The mass of Lp(a) was calculated with Lp(a)-p * 0.4167[17]. The total particles of cholesterol (TC-p), LDL-p and HDL-p, as well as the average size of LDL were measured with NMR (AvanceII IVDr, ProteinT®, Bruker®). Non-HDL-C = TC − HDL-C. The corrected LDL-C (LDL-C-corr) = LDL-C − 0.3 * Lp(a)[18, 19]. The corrected non-HDL-C (non-HDL-C-corr) = non-HDL-C − 0.3 * Lp(a). The particles of non-HDL (non-HDL-p) = TC-p − HDL-C-p. The corrected particles of LDL (LDL-p-corr) = LDL-p − Lp(a)-p. And the corrected particles of non-HDL (non-HDL-p-corr) = non-HDL-p − Lp(a)-p.

Statistical analysis

Categorical variables were presented as n (%), and the differences between groups were assessed with chi-square test. The continuous variables were tested with Kolmogorov–Smirnov for the normality of distributions and presented as mean ± standard deviations when normally distributed, medians (25th, 75th percentile) when non-normally distributed. Student’s t-test was used to assess the differences of continuous variables between groups, among which, the non-normally distributed ones were converted into natural logarithm before assessment. Multivariate Logistic regression analysis was performed for CHD risk factors detection by using forward stepwise selection process. Associations between variables and Gensini were assessed using Spearman correlation analysis. Receiver operating characteristic (ROC) for CHD were performed with routine and advanced lipid indexes,
and the area under curve (AUC) of advanced lipid items were compared with the routine ones. All statistical analysis was performed with Stata version 15. Data were considered statistically significant when \( P \) value was less than 0.05.

**Result**

**Clinical demography characteristics, routine and advanced lipid parameters**

300 patients were enrolled in this study, of which 58 patients were assigned into non-CHD Group. (Table 1) In the clinical demography comparisons, age and TIMI flow 0– were the variables with difference between two groups. Routine lipid indexes, TG, HDL-C and advanced lipid indexes, ApoB, TC-p, Lp(a)-p, Lp(a), LDL-size, HDL-p, non-HDL-C-porr were distributed on the skew. ApoB, TC-p, LDL-p, LDL-p-corr, non-HDL-C, non-HDL-C-corr, non-HDL-p and non-HDL-p-corr in CHD group were significantly higher than in non-CHD group.

**Risk factors of CHD**

The multivariate analysis of risk factors associated with CHD was displayed in Fig. 2. Among the 9 variables, Age (hazard ratio (HR) 2.58, 95% confidence interval (CI)

| Table 1: Clinical demography characteristics, routine and advanced lipids |
|-------------------------|------------------|------------------|----------|
|                         | Non-CHD group (n = 58) | CHD group (n = 242) | \( T/\chi^2 \) | \( P \) |
| Age, y                  | 58.86 ± 8.03       | 65.76 ± 8.46      | 5.628    | <0.001 |
| Smoking, No             | 7 (12.07%)         | 18 (7.44%)        | 1.708    | 0.252  |
| Overweight \(^a\), No   | 19 (32.76%)        | 65 (26.86%)       | 1.327    | 0.369  |
| Diabetes, No            | 19 (32.76%)        | 104 (42.98%)      | 2.022    | 0.155  |
| Hypertension, No        | 34 (58.62%)        | 143 (59.09%)      | 0.981    | 0.948  |
| Family history \(^b\), No | 11 (18.97%)       | 37 (15.29%)       | 1.297    | 0.493  |
| TIMI Flow 0–, No        | 0 (0.00%)          | 32 (13.22%)       | 8.585    | 0.003  |
| TG (mg/dL)*             | 133.92 (106.85, 200.46) | 148.82 (100.94, 209.08) | 0.394    | 0.694  |
| ApoA1 (mg/dL)           | 134.31 ± 15.94     | 130.41 ± 15.74    | 1.693    | 0.092  |
| ApoB (mg/dL)*           | 77.91 (58.51, 98.86) | 82.10 (68.75, 98.49) | 2.839    | 0.005  |
| TC-p (nmol/L)*          | 1416.58 (1063.81, 1633.81) | 1492.63 (1250.06, 1790.84) | 2.839    | 0.005  |
| TC (mg/dL)              | 168.16 ± 38.43     | 177.74 ± 38.68    | 1.696    | 0.091  |
| Lp(a)-p (nmol/L)*       | 42.80 (16.35, 93.88) | 36.40 (13.40, 80.00) | 0.801    | 0.424  |
| Lp(a) (mg/dL)*          | 17.83 (6.81, 39.12) | 14.96 (5.42, 33.12) | 0.801    | 0.424  |
| LDL-p (nmol/L)          | 1042.17 ± 360.58   | 1168.91 ± 366.35  | 2.374    | 0.018  |
| LDL-C (mg/dL)           | 81.15 ± 32.77      | 87.30 ± 30.60     | 1.354    | 0.177  |
| LDL-size (nm)*          | 20.44 (20.23, 20.68) | 20.37 (20.17, 20.61) | 1.634    | 0.103  |
| LDL-p-corr (nmol/L)     | 977.50 ± 357.33    | 1108.44 ± 366.46  | 2.456    | 0.015  |
| Lp(a)-p-corr (nmol/L)*  | 73.10 ± 32.30      | 79.76 ± 30.41     | 1.481    | 0.140  |
| HDL-p (nmol/L)*         | 73.35 (45.78, 121.62) | 78.87 (51.55, 114.60) | 0.747    | 0.455  |
| HDL-C (mg/dL)*          | 45.81 (38.86, 55.28) | 45.23 (40.46, 50.51) | 0.877    | 0.381  |
| Non-HDL-p (nmol/L)      | 1300.29 ± 381.68   | 1463.23 ± 424.55  | 2.675    | 0.008  |
| Non-HDL-p-corr (nmol/L) | 1235.62 ± 377.88   | 1402.67 ± 426.11  | 2.740    | 0.007  |
| Non-HDL-C (mg/dL)       | 120.62 ± 34.74     | 131.50 ± 37.68    | 2.004    | 0.046  |
| Non-HDL-C-corr (mg/dL)* | 112.53 (84.79, 136.45) | 116.96 (96.00, 147.17) | 2.148    | 0.033  |

TG, triglyceride; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; TC-p, total particles of cholesterol; TC, total cholesterol; Lp(a), lipoprotein a; Lp(a)-p, particles of Lp(a); LDL-C, low-density lipoprotein cholesterol; LDL-p, particles of LDL; LDL-size, average diameter of LDL-p; LDL-p-corr and LDL-C-corr, corrected LDL-p and LDL-C; HDL-C, high-density lipoprotein cholesterol; HDL-p, particles of HDL; non-HDL-C, none high-density lipoprotein cholesterol; non-HDL-p, particles of non-HDL; non-HDL-p-corr and non-HDL-C-corr, corrected non-HDL-p and non-HDL-C

\[ Lp(a)-p = Lp(a) - 0.3 \times Lp(a) \]

**TG, ApoB, TC-p, Lp(a)-p, Lp(a), LDL-C-size, HDL-C and non-HDL-C-corr were skew distribution and shown as median (25th percentile, 75th percentile). Before the Student’s t-test for the difference between groups, the nonnormal distribution variables were converted into natural logarithm form**

\(^a\) Overweight was defined as body mass index (BMI) > 28 (BMI = weight (Kg) / height (m))

\(^b\) Family history was defined as the age of onset of coronary heart disease less than 55 for men and less than 65 for women, in the immediate family members of patients

\(^c\) TIMI flow classification was used to evaluate coronary artery perfusion by coronary angiography. It was divided into grade 0 (no perfusion); Grade 1 (infiltration without perfusion); Grade 2 (partial perfusion) and Grade 3 (complete perfusion)
1.08–5.86, \( P = 0.03 \), ApoB (HR 1.35, 95% CI 1.15–1.59, \( P < 0.001 \)), LDL-p-corr (HR 1.05, 95% CI 1.03–1.06, \( P < 0.001 \)) and non-HDL-p-corr (HR 1.02, 95% CI 1.01–1.03, \( P < 0.001 \)) were risk factors of CHD.

**Correlation analysis of lipid indexes and Gensini score**

Figure 3 showed the Spearman correlation analysis of routine, advanced lipid indexes and Gensini score. In general, LDL-C, LDL-p, LDL-p-corr, HDL-C, non-HDL-C, non-HDL-p and non-HDL-p-corr were in linear correlation with Gensini score. The correlation coefficient \( r \) ranged in 0.203 of LDL-p-corr to 0.242 of non-HDL-C-p. There was no significant difference in the comparison between routine and advanced lipid items in the correlation analysis with Gensini.

**Predictive ability of routine and advanced lipid indexes for CHD**

In the ROCs, displayed in Fig. 4, the most predictive lipid index for CHD was LDL-p-corr, with AUC = 0.759, cutoff of 97.12 nmol/L, while the weakest one was HDL-p with AUC = 0.519. The routine lipid items, HDL-C, LDL-C, non-HDL-C and TC were set as the standards in the comparison of the predictive powers. Advanced lipid indexes, LDL-p (\( P = 0.02 \)) and LDL-p-corr (\( P = 0.02 \)) were more predictive than the standard (LDL-C), while LDL-size (\( P = 0.009 \)) and LDL-C-corr (\( P = 0.03 \)) were less than LDL-C. The predictive capability of non-HDL-p (\( P = 0.03 \)) and non-HDL-p-corr (\( P = 0.03 \)) were also stronger than standard (non-HDL-C). Among all lipid indexes, the most sensitive one for CHD was HDL-C (sensitivity, 86.8%), and the most specific was non-HDL-C (specificity, 94.8%).

**Discussion**

The recently published study showed a difference of disability adjusted life year (DALY) due to CVD between sexes that the total CVD DALYs of male were significantly higher than female at the age of 30–60, but the relation reversed after 80–84 [20]. In this study, we found age as the most important risk factor of CHD in a group of elderly, postmenopausal women. It is known to all that the morbidity of CHD, hypertension, DM and metabolic syndrome increased with age. Besides, age is also a factor influencing the efficacy of hormone replacement therapy for postmenopausal women [21]. Recently published 10-year follow-up results of the BRECARD Study [22] indicated that the higher the content of breast adipose tissue, the higher the incidence of MACE in pre-menopausal women. In addition to the traditional risk factors, adipokines may play an important role in atherosclerosis.
process in elder people [23]. We hypothesize that adipokines are involved in lipid metabolism, fat deposition (increased body mass index) and redistribution (at accumulation in breast, abdomen and other trunk positions) and inflammation, which contribute to the abnormal lipid metabolism and atherosclerosis.

The results of this study also indicated that compared with routine lipid indexes LDL-C and non-HDL-C, the advanced ones, LDL-p, LDL-p-corr, non-HDL-p and non-HDL-p-corr were more predictive for CHD in postmenopausal women. Due to the similarity of Lp(a) and LDL-C, both the traditional lipid panel and NMR reported LDL-C was a mixture of LDL-C and Lp(a). It was reported that 30%-45% LDL-C in traditional lipid panel was contributed by Lp(a) and in more extreme cases, the majority of LDL-C was carried by Lp(a) when LDL-C less than 25 mg/dL [24]. To distinguish the pathogenic role of Lp(a) and LDL-C in atherosclerosis, 0.3*Lp(a) (mg/dL) and LDL-C-corr (LDL-C – 0.3*Lp(a)) was used in several studies, as cholesterol account for 30%-45% of Lp(a) particle [18, 25]. Those two lipid items are focused on the pathogenic effect of cholesterol in both Lp(a) and LDL-C, but the LDL-p and Lp(a)-p are also strong predictors of CHD. In this study, we measured Lp(a)-p in nmol/L with Tina-quant Lipoprotein (a) Gen.2, a latex coated antibody of apo(a), and the accuracy were higher among six common commercial assays [26]. Furthermore, we made an innovation of LDL-p-corr and non-HDL-p-corr, which mean pure particles of LDL and non-HDL. As we know, these two lipid items initiated by us have not been studied before. Our study proved that LDL-p-corr and non-HDL-p-corr were risk factors of CHD and significantly correlated with Gensini score in postmenopausal women.

Fig. 3 Spearman correlation analysis between routine, advanced lipid indexes and Gensini score. Associations between variables and Gensini were assessed with Spearman correlation analysis. TC, total cholesterol; TC-p, total particles of cholesterol; LDL-C, low-density lipoprotein cholesterol; LDL-p, particles of LDL; LDL-C-corr, the correction of LDL-C; LDL-p-corr, the correction of LDL-p; HDL-C, high-density lipoprotein cholesterol; HDL-p, particles of HDL; non-HDL-C-corr, correction of non-HDL-C; non-HDL-p, particles of non-HDL; non-HDL-p-corr, correction of non-HDL-p. LDL-C-corr = LDL-C – 0.3*lipoprotein a (Lp(a)); LDL-p-corr = LDL-p – particles of Lp(a) (Lp(a)-p); non-HDL-C-corr = TC – HDL-C; non-HDL-C = TC – HDL-C; non-HDL-p-corr = non-HDL-p – Lp(a)-p.
In the ROCs, we found HDL-C was the traditional blood lipid item with the weakest predictive ability for CHD, with the AUC under 0.50. It was consistent with the current view of the relationship between HDL and CHD [27]. In the comparison of predictive abilities between traditional and advanced lipid items, the predictive abilities of LDL-p, LDL-p-corr, non-HDL-p and non-HDL-p-corr were significantly stronger than the traditional lipid items, LDL-C and non-HDL-C. That indicated the particles of LDL and non-HDL may be better lipid indexes in CHD prevention. However, whether this finding is a general feature of the population or only confined to postmenopausal women remains to be confirmed by further studies.

There are several limitations of this study. First, over 80% of the study population were diagnosed with CHD, the result can't represent the general characteristics of postmenopausal women. Second, menopause status came from the patients' reports, more than 30% of the study population could not provide accurate menopause time, we took age as the risk factor of CHD, and it will be more precise if the postmenopausal time or serum sex hormones were available. But the age was not well matched between two groups and the differences of CHD risk factors and metabolic indexes can't be ruled out whether it is caused by age. Third, limited by the cross-sectional design, reversal causality is possible. For example, we couldn't confirm whether ApoB, LDL-p-corr and...
non-HDL-p-corr were pathogenic factors of CHD or just the metabolic characteristics of postmenopausal women with CHD. Finally, further research is needed to confirm the stability of lipid indexes in frozen samples and repeatability of the advanced lipid measurement.

**Conclusion**

In postmenopausal females, age, ApoB, corrected particles of LDL and non-HDL are risk factors of CHD. LDL-C, non-HDL-C, LDL-p-corr and non-HDL-p-corr were positively correlated with coronary plaque burden, while C, non-HDL-C, LDL-p-corr and non-HDL-p-corr were pathogenic factors of CHD. LDL-p: Particles of LDL; LDL-size: Average diameter of LDL; LDL-C-corr: Corrected LDL cholesterol; non-HDL-p-corr: Corrected particles of non-HDL; non-HDL-C: Non-HDLC; non-HDL-p: Particles of non-HDL; non-HDL-C-corr: Corrected non-HDL-C; non-HDL-p-corr: Corrected particles of non-HDL; Lp(a): Lipoprotein a; Lp(a)-p: Particles of Lp(a); ApoB: Apolipoprotein B; E2: Estradiol; PCSK9: Proprotein convertase subtilisin/kexin type-9; C-RP: C-reactive protein; NMR: Nuclear magnetic resonance; CAG: Coronary angiography; PCI: Percutaneous coronary intervention; CABG: Coronary artery bypass graft; LVEF: Left ventricular ejection fraction.

**Authors’ contributions**

Dr. MZ put forward research ideas and was responsible for the organization of research. Dr. YSC, XN and WC provided parts of patients and data sources. CL was responsible for data collection and article writing. Authors all read and approved the final manuscript.

**Funding**

This study was supported by Key Projects of Tianjin Natural Science Foundation, Tianjin, China (No. 16JCZDJC31900) and Special Project on Health Care of the Cardiovascular Institute of Special Medical Center of Chinese People’s Armed Police Force.

**Availability of data and materials**

All data generated or analyzed during this study are included in this published article.

**Declarations**

**Ethics approval and consent to participate**

This study has been approved by the Ethics Committee of Special Medical Center of Chinese Armed Police Force in accordance with the Helsinki Declaration. All the patients had been informed about the rights and obligations in this study and signed in informed consent before took part in.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1. Department of Thoracic and Cardiovascular Surgery, Special Medical Center of Chinese People’s Armed Police Force, 220 Chenglin Road, Tianjin 300162, China. 2. School of Engineering, Chinese University of Hong Kong, Hong Kong, China. 3. W.P. Carey School of Business, Arizona State University, Tempe, Arizona, USA. 4. Tianjin Beichen Hospital, Beichen, Tianjin, China.

**Received** 29 March 2021 **Accepted** 13 July 2021 **Published online** 02 August 2021

**References**

1. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Das SR, et al. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56–528.

2. Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, Kahn J, Afonso L, Williams KA Sr, Flack JM. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012;60(25):2631–9.

3. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227–39.

4. Thurston RC, Karvonen-Gutierrez CA, Derby CA, El Khoudary SR, Kravit HM, Manson JE. Menopause versus chronologic aging: their roles in women’s health. Menopause (New York, NY). 2018;25(8):849–54.

5. Matthews KA, Crawford SL, Chae CU, Everson-Rose SA, Sowers MF, Sternfeld B, Sutton-Tyrrell K. Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? J Am Coll Cardiol. 2009;54(25):2366–73.

6. Cervellati C, Bergamini CM. Oxidative damage and the pathogenesis of menopause related disturbances and diseases. Clin Chem Lab Med. 2016;54(5):739–53.

7. Takahashi TA, Johnson KM. Menopause. Med Clin N Am. 2015;99(3):521–34.

8. Sardu C, Paolisso G, Marfella R. Impact of sex differences in incident and recurrent coronary events and all-cause mortality. J Am Coll Cardiol. 2021;77(6):829–30.

9. Marek F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88.

10. Yan XN, Jin JL, Hong LF, Guo YL, Wu NQ, Zhu CG, Dong Q, Li JJ. Lipoprotein(a) is associated with the presence and severity of new-onset coronary artery disease in postmenopausal women. J Women’s Health (2002) 2020;29(4):503–10.

11. Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation. 2009;119(7):931–9.

12. Mackey RH, McGtigue KM, Chang YF, Barinas-Mitchell E, Evans RW, Tinker LF, Lewis CE, Manson JE, Stefanick ML, Howard BV, et al. Lipoprotein particles and size, total and high molecular weight adiponectin, and leptin in relation to incident coronary heart disease among severely obese postmenopausal women: the Women’s Health Initiative Observational Study. BBA clinical. 2015;3:243–50.

13. Mackey RH, Keller LH, Sutton-Tyrrell K, Evans RW, Holubkova R, Matthews KA. Lipoprotein subclasses and coronary artery calcium in postmenopausal women from the healthy women study. Am J Cardiol. 2002;90(8A):711–6.

14. Keller L, Arnold A, Tracy R, Otvos J, Burke G, Psaty B, Siscovick D, Freedman DS, Kronmal R. Nuclear magnetic resonance spectroscopy of lipoproteins.
and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vasc Biol. 2002;22(7):1175–80.

15. Patel MR, Peterson ED, Dai D, Brennan JM, Redberg RF, Anderson HV, Brindis RG, Douglas PS. Low diagnostic yield of elective coronary angiography. N Engl J Med. 2010;362(10):886–95.

16. Neeland IJ, Patel RS, Esthearti P, Dhawan S, McDaniel MC, Rab ST, Vaccarino V, Zafari AM, Samady H, Quyyumi AA. Coronary angiographic scoring systems: an evaluation of their equivalence and validity. Am Heart J. 2012;164(4):547–52.

17. Nordestgaard BG, Chapman MJ, Ginsberg HN. Lipoprotein(a): EAS recommendations for screening, desirable levels and management: a handbook for clinicians paperback. 2012 (1) Sherborne Gibbs Limited, pp. 1–2.

18. Marcovina SM, Albers JJ, Scannu AM, Kennedy H, Giaculli F, Berg K, Couderc R, Dati F, Rifai N, Sakurabayashi I, et al. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem. 2000;46(12):1956–67.

19. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713–22.

20. Roth GA, Mensah GA, Johnson CQ, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76:2982–3021.

21. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science (New York, NY). 2005;308(5728):1583–7.

22. Sardu C, Gatta G, Peretti G, Viola L, Sacra C, Di Grezia G, Musto L, Minelli S, La Forgia D, Capodieci M, et al. Pre-menopausal breast fat density might predict MACE during 10 years of follow-up: the BRECARD study. JACC Cardiovasc Imaging. 2021;14(2):426–38.

23. Sassu FC, Pafundi PC, Marfella R, Galabio P, Picione F, Furbatto F, Esposito G, Galleo R, Gragnano F, Rinaldi L, et al. Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: the prospective AIRE study. Cardiovasc Diabetol. 2019;18(1):24.

24. Yeung C, Witzum JL, Tsimikas S. “LDL-C” = LDL-C + Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era of potent LDL-C lowering. Curr Opin Lipidol. 2015;26(3):169–78.

25. Schwartz GG, Stieg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097–107.

26. Scharnagl H, Stojsicovic T, Dieplinger B, Dieplinger H, Erhart G, Kostner GM, Herrmann M, Marz W, Grammer TB. Comparison of lipoprotein(a) serum concentrations measured by six commercially available immunoassays. Atherosclerosis. 2019;289:206–13.

27. Rodriguez A. High HDL-cholesterol paradox: SCARB1-LAG3-HDL axis. Curr Atheroscler Rep. 2021;23(1):5.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions